(+) (+) ( ) 2012 ASH Abstract #3972 Kumar - - PowerPoint PPT Presentation

▶
2012 ash abstract 3972 kumar et al
SMART_READER_LITE
LIVE PREVIEW

(+) (+) ( ) 2012 ASH Abstract #3972 Kumar - - PowerPoint PPT Presentation

Sep 02, 2023 343 likes •929 views

(+) (+) ( ) 2012 ASH Abstract #3972 Kumar et al 1:1 1:1 Median Follow Up: 36 Months 100 100 80 80 60 60 40 40 20 20 0 0 0 6 12

slide-1
SLIDE 1
slide-2
SLIDE 2
slide-3
SLIDE 3

(+) (–) (+)

slide-4
SLIDE 4
  • “

” – – –

slide-5
SLIDE 5
slide-6
SLIDE 6
slide-7
SLIDE 7
slide-8
SLIDE 8
slide-9
SLIDE 9

2012 ASH Abstract #3972 Kumar et al

slide-10
SLIDE 10

’

slide-11
SLIDE 11

1:1 1:1

slide-12
SLIDE 12
slide-13
SLIDE 13
slide-14
SLIDE 14

Median Follow Up: 36 Months

slide-15
SLIDE 15

0 6 12 18 24 30 36 100 80 60 40 20 0 6 12 18 24 30 36 100 80 60 40 20

Rd RD

slide-16
SLIDE 16

1

Probability of OS

1.00 0.75 0.50 0.25

4 5 6 7 8 CR + VGPR (n = 445) PR (n = 288) 1 2 3 P = .0017 Probability of OS 1.00 0.8 0.4 0.2 4 5 6 7 CR or better VGPR 1 2 3 0.6 PR SD PD

slide-17
SLIDE 17
slide-18
SLIDE 18
slide-19
SLIDE 19
slide-20
SLIDE 20
slide-21
SLIDE 21
slide-22
SLIDE 22
slide-23
SLIDE 23
slide-24
SLIDE 24

IgA remained normal Kappa light chain rose Renal failure on Dialysis Short lived response to High Dose Melphalan

HD melphalan

slide-25
SLIDE 25
slide-26
SLIDE 26
slide-27
SLIDE 27

27

slide-28
SLIDE 28
slide-29
SLIDE 29
slide-30
SLIDE 30
slide-31
SLIDE 31

10 20 30 40 50 100 80 60 40 20

Time to progression (%)

P-value : p<0.0001 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

Patients without progression (%)

6 12 18 24 30 36 42 48

slide-32
SLIDE 32

P-value : p=0.0007 Negative (<10-6) Positive 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

47 47 (0) 47 (0) 47 (0) 41 (5) 33 (7) 24 (6) 4 (7) 3 (1) MRD positive 36 36 (0) 36 (0) 36 (0) 36 (0) 30 (3) 24 (1) 14 (2) 6 (0) MRD neg (<10

  • 6)

N at risk (events)

6 12 18 24 30 36 42 48

Months since randomization

MRD at post-maintenance for arm A

P-value : p<0.0001 Negative (<10-6) Positive 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

Patients without progression (%)

45 45 (0) 45 (0) 45 (0) 42 (2) 31 (10) 21 (5) 7 (6) 2 (0) MRD positive 50 50 (0) 50 (0) 50 (0) 50 (0) 47 (2) 37 (2) 22 (3) 4 (0) MRD neg (<10

  • 6)

N at risk (events)

6 12 18 24 30 36 42 48

Months since randomization

MRD at post-maintenance for arm B

slide-33
SLIDE 33
slide-34
SLIDE 34
slide-35
SLIDE 35
slide-36
SLIDE 36
slide-37
SLIDE 37

18% 10%

1%

2%

5 10 15 20 25 30 35 16 mg/kg ORR, %

PR VGPR CR sCR

ORR = 31%

3% CR or better 13% VGPR or better N = 148

slide-38
SLIDE 38

Responders MR/SD PD/NE

slide-39
SLIDE 39
slide-40
SLIDE 40
slide-41
SLIDE 41
slide-42
SLIDE 42
slide-43
SLIDE 43
slide-44
SLIDE 44
slide-45
SLIDE 45
slide-46
SLIDE 46

Elotuzumab CD16

slide-47
SLIDE 47
  • 6
slide-48
SLIDE 48

─ ─ ─ ─ ─ ─ ─

slide-49
SLIDE 49
slide-50
SLIDE 50
slide-51
SLIDE 51
  • T Cell

Anti-BCMA

T Cell Anti-BCMA T Cell Anti-BCMA T Cell Anti-BCMA

slide-52
SLIDE 52
slide-53
SLIDE 53

1 1 2 8

slide-54
SLIDE 54

×

slide-55
SLIDE 55
slide-56
SLIDE 56
slide-57
SLIDE 57
slide-58
SLIDE 58